The content on this site is intended for healthcare professionals only
Dr Landier presents, at a press conference at ASH 2015, results from a study looking at 6-Mercaptopurine (6MP) intake during maintenance for childhood acute lymphoblastic leukaemia.
The study was conducted by the Children's Oncology Group, comparing self-report and electronic monitoring.
Read the news story and watch the video interview for more information.
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia
